Skip to main content
SpringerLink
Log in

Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Narcolepsy is currently treated with antidepressants to control REM-related symptoms such as cataplexy and with amphetamine-like stimulants for the management of sleepiness. Both stimulant and antidepressant drugs presynaptically enhance monoaminergic transmission but both classes of compounds lack pharmacological specificity. In order to determine which monoamine is selectively involved in the therapeutic effect of these compounds, we examined the effects of selective monoamine uptake inhibitors and release enhancers on cataplexy using a canine model of the human disorder. A total of 14 compounds acting on the adrenergic (desipramine, nisoxetine, nortriptyline, tomoxetine, viloxazine), serotoninergic (fenfluramine, fluoxetine, indalpine, paroxetine, zimelidine) and dopaminergic (amfonelic acid, amineptine, bupropion, GBR 12909) systems were tested. Some additional compounds interesting clinically but with less pharmacological selectivity, i.e., cocaine, dextroamphetamine, methylphenidate, nomifensine and pemoline, were also included in the study. All compounds affecting noradrenergic transmission completely suppressed canine cataplexy at low doses in all dogs tested, whereas compounds which predominantly modified serotoninergic and dopaminergic transmission were either inactive or partially active at high doses. Our results demonstrate the preferential involvement of adrenergic systems in the control of cataplexy and, presumably, REM sleep atonia. Our findings also demonstrate that canine narcolepsy is a useful tool in assessing the pharmacological specificity of antidepressant drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aldrich M(1992) Narcolepsy. Neurology 42:34–43

    Google Scholar 

  • Andersen PH (1989) The dopamine uptake inhibitor. GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493–504

    Google Scholar 

  • Appel NM, Mitchell WMM, Contrera JF, De Souza EB (1990) Effects of high dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse 6:33–44

    Google Scholar 

  • Babcock DA, Narver EL, Dement WC, Mitler MM (1976) Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 5:599–602.

    Google Scholar 

  • Baker T, Dement WC (1985) Canine narcolepsy-cataplexy syndrome; evidence for an inherited monoaminergic-cholinergic imbalance. In: DJ McGinty, Drucker-Collin R, Morrison A, Parmeggiani P (eds) Brain mechanisms of sleep. Raven, New York, pp 199–233

    Google Scholar 

  • Bertilsson L, Tuck JR, Siwers B (1980) Biochemical effects of Zimelidine in man. Eur J Pharmacol 18:483–487

    Google Scholar 

  • Brogden RN, Heel RC, Speight TM, Avery GS (1979) Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18:1–24

    Google Scholar 

  • Buus Lassen J, Squires F, Christensen JA, Molander L (1975) Neurochemical and pharmacological studies on a new 5-HT uptake inhibitor, FG 4963, with potential antidepressant properties. Psychopharmacology 42:21–26

    Google Scholar 

  • Cadilhac J (1976) Tricyclic and REM sleep. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum, New York, pp 605–623

    Google Scholar 

  • Chouinard G, Annabel L, Bradwejn J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126–128

    Google Scholar 

  • Ferris RM, Beaman OJ (1983) Bupropion; a new antidepressant drug, the mechanism of action of which is not associated with down regulation of postsynaptic beta-adrenergic, serotoninergic (5-HT2), alpha-2 adrenergic, imipramine and dopaminergic receptors in the brain. Neuropharmacology 22[11] 1257–1983

    Google Scholar 

  • Fuller RW, Snoddy HD, Molloy BB (1975) Blockade of amine depletion by nisoxetine in comparison to other uptake inhibitors. Psychopharmacol Commun 1[5]:455–464

    Google Scholar 

  • Gaillard JM, Kafi S (1979) Involvement of pre- and postsynaptic receptors in catecholaminergic control of paradoxical sleep in man. Eur J Clin Pharmacol 15:83–89

    Google Scholar 

  • Garattini S, Mennini T (1988) Critical notes on the specificity of drugs in the study of metabolism and functions of brain monoamines. Inter Rev Neurobiol 29:259–280

    Google Scholar 

  • Garattini S, Mennini T (1989) Pharmacology of amineptine: synthesis and update. Clin. Neuropharmacol (Suppl 2) 12:S13-S18

    Google Scholar 

  • Glowinski J, Axelrod J (1964) Inhibition of uptake of tritiated noradrenaline in intact brain by imipramine and structurally related compounds. Nature, 204:1318–1320

    Google Scholar 

  • Guilleminault C, Mancuso J, Quera Salva MA, Hayes B, Mitler M, Poirier G. Montplaisir J (1986) Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 9 [1] 275–279

    Google Scholar 

  • Heikkila RE, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241–248

    Google Scholar 

  • Hishikawa Y, Ida H, Nakai K, Kaneko Z (1966) Treatment of narcolepsy with imipramine and desmethylimipramine. J Neurol Sci 3:453–459

    Google Scholar 

  • Johnson AM (1989) An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl 350:14–20

    Google Scholar 

  • Kafi-De St Hilaire S, Merica H, Gaillard JM (1984) The effects of indalpine — a selective inhibitor of 5-HTuptake — on rat paradoxical sleep. Eur J Pharmacol 98:413–418

    Google Scholar 

  • Karczmar AG, Longo VG, Scotti de Carolis A (1970) A pharmacological model of paradoxical sleep: The role of cholinergic and monoaminergic systems. Physiol Behav 5:175–182.

    Google Scholar 

  • Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. TIPS 14[7]:299–302

    Google Scholar 

  • Langdon N, Shindler J, Parkes JD, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9[2]:371–373

    Google Scholar 

  • Lefur G, Uzan A (1977) Effects of 4-(3-indolylalkyl) piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol 26:497–503

    Google Scholar 

  • McMillen BA (1983) CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. TIPS 10:429–432

    Google Scholar 

  • McMillen BA, Scott SM, Williams HL (1991) Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotoninergic function. J. Neural Transm [GenSect] 83:55–66

    Google Scholar 

  • McTavish D, Hell RC (1992) Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 43[5]:713–733

    Google Scholar 

  • Mignot E, Guilleminault C, Bowersox S, Rappaport A, Dement WC (1988) A role of central alpha 1 adrenoceptors in canine narcolepsy. J Clin Invest 82:885–894

    Google Scholar 

  • Mignot E, Guilleminault C, Dement WC, Grumet C (1992) Genetically determined animal models of narcolepsy, a disorder of REM sleep. In: Driscoll D (ed) Genetically determined animal models of neurobehavioral dysfunction. Birkhauser Boston Cambridge, pp 90–110

    Google Scholar 

  • Mignot E, Nishino S, Hunt-Sharp L, Arrigoni J, Siegel JM, Reid MS, Edgar D, Ciaranello RD, Dement WC (1993) Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymtomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 13[3]:1057–1064

    Google Scholar 

  • Mitler MM, Hadjucovic R (1991) Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 14:218–220

    Google Scholar 

  • Montplaisir J, Godbout R (1986) Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 9[1]:280–284

    Google Scholar 

  • Monti JM (1983) Minireview: catecholamines and the sleep wake cycle. Life Sci 32:1401–1415

    Google Scholar 

  • Nicholson AN, Pascoe PA (1988) Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacol, 27[6]:597–602

    Google Scholar 

  • Nicholson AN, Pascoe PA (1986) 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25[10]:1079–1083

    Google Scholar 

  • Nicholson AN, Pascoe PA (1990) Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology 29[4]:411–417

    Google Scholar 

  • Nishino S, Haak L, Shepperd H, Guilleminault C, Sakai T, Dement WC, Mignot E (1990) Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of REM sleep. J Pharmacol Exp Ther 253[3]:1145–1152

    Google Scholar 

  • Nishino S, Arrigoni J, Valtier D, Miller J, Guilleminault, C, Dement WC, Mignot E (1991) Involvement of dopamine D2-type receptors in the regulation of cataplexy in canine narcolepsy. J Neurosci 11:2666–2671

    Google Scholar 

  • Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106–112

    Google Scholar 

  • Ogren SO, Ross SB, Hall H, Holm AC, Renyi AL (1981) The pharmacology of zimelidine: A 5-HT selective reuptake inhibitor Acta Psychiatr Scand Suppl 290 [63]:127–151

    Google Scholar 

  • Parkes D (1976) Amphetamine and alertness. In: Guilleminault C, Passouant P, Dement WC (eds) Narcolepsy. Spectrum New York pp 643–658

    Google Scholar 

  • Pinder RM, Brodgen RN, Speight TM, Avery GS (1977) Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13:401–421

    Google Scholar 

  • Pliska V (1987) Dose-response models: similarity with population growth dynamics. TIPS 8:50–52

    Google Scholar 

  • Polc P, Schneeberger J, Haefely W (1979) Effects of several centrally active drugs on the sleep-wakefulness cycle in cats. Neuropharmacology 18:259–265

    Google Scholar 

  • Richelson E (1984) The newer antidepressants: structures, pharmacokinetics, pharmacodynamics and proposed mechanisms of action. Psychopharmacol Bull 20[2]:213–223

    Google Scholar 

  • Richelson E. Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–186

    Google Scholar 

  • Ross RJ, Ball WA, Gresch PJ, Morrison AR (1990) REM sleep suppression by monoamine reuptake blockade: development of tolerance with repeated drug administration. Biol Psychiatry 28:231–239

    Google Scholar 

  • Rudorfer MV, Potter WZ (1989) Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the newer versus the older drugs. Drugs 37:713–738

    Google Scholar 

  • Saletu B, Frey R, Kruptka M, Anderer P, Grunberger J, See WR (1991) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14[5]:439–447

    Google Scholar 

  • Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 43:171–174

    Google Scholar 

  • Schrader H, Kayed K, Bendixen Markset B, Treidene HE (1986) The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 74:297–303

    Google Scholar 

  • Siegel JM (1989) Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC (eds) Principles and practice of sleep medicine. Saunders, Philadelphia, pp 104–120

    Google Scholar 

  • Sommi RW, Crismon ML, Bowden CL (1987) Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy 7 [1]:001–015

    Google Scholar 

  • Soroko FE, Mehta NB, Maxwell RA, Ferris RM, Schroeder DH (1977) Bupropion hydrochloride [(±) alpha-t-butylamino-3-chloropiophenone HCl]: a novel antidepressant agent. J Pharm Pharmacol 29:767–770

    Google Scholar 

  • Steriade M, McCarley R (eds) (1990) Brainstem control of wakefulness and sleep. Plenum, New York

    Google Scholar 

  • Tejani-Butt SM, Brunswick DJ, Frazer A (1990) [3H]-Nisoxetine: a new radioligand for norepinephrine uptake sites in brain. Eur J Pharmacol 191:239–243

    Google Scholar 

  • Tulloch IA, Johnson AM (1992) The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry (suppl) 53[2]:7–12

    Google Scholar 

  • Waldmeier PC (1982) Effects of antidepressant drugs on dopamine uptake and metabolism. J Pharm Pharmacol 34:391–394

    Google Scholar 

  • Wong DT, Bymaster FP, Reid LR, Threlkeld PG (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32[7]:1287–1293

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Sleep Disorders Center, Stanford University, 701 Welch Road, Suite 2226, 94304, Palo Alto, CA, USA

    Emmanuel Mignot, Alain Renaud, Seiji Nishino, Janis Arrigoni, Christian Guilleminault & William C. Dement

Authors
  1. Emmanuel Mignot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alain Renaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seiji Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janis Arrigoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Guilleminault
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William C. Dement
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mignot, E., Renaud, A., Nishino, S. et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 113, 76–82 (1993). https://doi.org/10.1007/BF02244337

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02244337

Key words

Search

Navigation